Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aspen Pharmacare stock logo
APNHY
Aspen Pharmacare
$6.60
-2.7%
$6.82
$5.76
$13.69
N/A0.982,814 shs566 shs
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
$27.73
$27.13
$22.56
$28.92
$6.15B0.57100 shsN/A
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
$37.09
-1.2%
$32.63
$21.10
$37.53
$10.59B0.07141 shs124 shs
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
$24.38
-1.2%
$24.38
$18.50
$31.96
$6.64B1.811,665 shs200 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aspen Pharmacare stock logo
APNHY
Aspen Pharmacare
-2.73%-0.98%-0.08%-28.20%-50.93%
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
0.00%0.00%0.00%+5.86%+9.82%
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
-1.17%+1.81%+12.29%+24.46%+74.09%
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aspen Pharmacare stock logo
APNHY
Aspen Pharmacare
N/AN/AN/AN/AN/AN/AN/AN/A
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
N/AN/AN/AN/AN/AN/AN/AN/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aspen Pharmacare stock logo
APNHY
Aspen Pharmacare
0.00
N/AN/AN/A
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
3.50
Strong BuyN/AN/A
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
2.00
HoldN/AN/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ORINY, HKMPF, SWTUY, and APNHY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aspen Pharmacare stock logo
APNHY
Aspen Pharmacare
$2.39BN/A$1.04 per share6.35$10.90 per shareN/A
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
$3.13B1.97$2.23 per share12.43$10.46 per share2.65
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
$1.67B6.27$1.60 per share23.16$3.85 per share9.63
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
$763.19M8.71$0.70 per share34.66$2.88 per share8.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aspen Pharmacare stock logo
APNHY
Aspen Pharmacare
$235.61MN/A0.006.53N/AN/AN/AN/A9/3/2025 (Estimated)
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
$359MN/A0.00N/AN/AN/AN/A8/7/2025 (Estimated)
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
$356.98M$1.3128.3128.53N/A21.74%36.23%21.28%7/18/2025 (Estimated)
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
$134.73M$0.5048.7616.931.3025.75%29.63%18.74%N/A

Latest ORINY, HKMPF, SWTUY, and APNHY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/23/2025Q1 2025
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
N/A$0.23N/A$0.23N/A$373.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aspen Pharmacare stock logo
APNHY
Aspen Pharmacare
$0.121.82%N/AN/AN/A
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
$0.963.46%N/AN/AN/A
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
$0.320.86%N/A24.43%N/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aspen Pharmacare stock logo
APNHY
Aspen Pharmacare
0.36
2.35
1.25
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
0.28
1.14
0.65
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
0.27
3.79
2.27
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aspen Pharmacare stock logo
APNHY
Aspen Pharmacare
N/A
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
N/A
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
N/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Aspen Pharmacare stock logo
APNHY
Aspen Pharmacare
9,350N/AN/ANot Optionable
Hikma Pharmaceuticals Plc stock logo
HKMPF
Hikma Pharmaceuticals
9,500221.89 millionN/ANot Optionable
Orion OYJ Unsponsored ADR stock logo
ORINY
Orion OYJ
3,712282.27 millionN/ANot Optionable
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
902272.51 millionN/ANot Optionable

Recent News About These Companies

RBC Capital Remains a Buy on Swedish Orphan Biovitrum AB (0MTD)
Exploring Sweden's High Growth Tech Giants

Media Sentiment Over Time

Aspen Pharmacare stock logo

Aspen Pharmacare OTCMKTS:APNHY

$6.60 -0.19 (-2.73%)
As of 06/24/2025 03:08 PM Eastern

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.

Hikma Pharmaceuticals stock logo

Hikma Pharmaceuticals OTCMKTS:HKMPF

$27.73 0.00 (0.00%)
As of 06/20/2025

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Orion OYJ stock logo

Orion OYJ OTCMKTS:ORINY

$37.09 -0.44 (-1.17%)
As of 06/24/2025 03:02 PM Eastern

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

SWEDISH ORPHAN/S stock logo

SWEDISH ORPHAN/S OTCMKTS:SWTUY

$24.38 -0.29 (-1.18%)
As of 04/9/2019

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.